These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10380067)

  • 1. Effects of sucrose, citric buffer and glucose oxidase on the stability of captopril in liquid formulations.
    Liu J; Chan SY; Ho PC
    J Clin Pharm Ther; 1999 Apr; 24(2):145-50. PubMed ID: 10380067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability of captopril in invert sugar solution.
    Sam WJ; Ho PC
    J Clin Pharm Ther; 1998 Dec; 23(6):451-6. PubMed ID: 10048506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term stability of extemporaneously prepared captopril oral liquids in glass bottles.
    Brustugun J; Lao YE; Fagernaes C; Braenden J; Kristensen S
    Am J Health Syst Pharm; 2009 Oct; 66(19):1722-5. PubMed ID: 19767378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of an alternative extemporaneous captopril fast-dispersing tablet formulation versus an extemporaneous oral liquid formulation.
    Pabari RM; McDermott C; Barlow J; Ramtoola Z
    Clin Ther; 2012 Nov; 34(11):2221-9. PubMed ID: 23149007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ingredients on stability of captopril in extemporaneously prepared oral liquids.
    Lye MY; Yow KL; Lim LY; Chan SY; Chan E; Ho PC
    Am J Health Syst Pharm; 1997 Nov; 54(21):2483-7. PubMed ID: 9359955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of formulation properties on chemical stability of captopril in aqueous preparations.
    Kristensen S; Lao YE; Brustugun J; Braenden JU
    Pharmazie; 2008 Dec; 63(12):872-7. PubMed ID: 19177902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physicochemical stability of captopril and enalapril extemporaneous formulations for pediatric patients.
    Casas M; Álvarez J; Lucero MJ
    Pharm Dev Technol; 2015 May; 20(3):271-8. PubMed ID: 24279906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of extemporaneously prepared saquinavir formulations.
    Tan LK; Thenmozhiyal JC; Ho PC
    J Clin Pharm Ther; 2003 Dec; 28(6):457-63. PubMed ID: 14651667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of captopril in SyrSpend SF.
    Geiger CM; Sorenson B; Whaley PA
    Int J Pharm Compd; 2013; 17(4):336-8. PubMed ID: 24261148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of the SeDeM diagram expert system for the formulation of Captopril SR matrix tablets by direct compression.
    Saurí J; Millán D; Suñé-Negre JM; Pérez-Lozano P; Sarrate R; Fàbregas A; Carrillo C; Miñarro M; Ticó JR; García-Montoya E
    Int J Pharm; 2014 Jan; 461(1-2):38-45. PubMed ID: 24284019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality evaluation of extemporaneous delayed-release liquid formulations of lansoprazole.
    Melkoumov A; Soukrati A; Elkin I; Forest JM; Hildgen P; Leclair G
    Am J Health Syst Pharm; 2011 Nov; 68(21):2069-74. PubMed ID: 22011986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability of captopril in some aqueous systems.
    Pramar Y; Das Gupta V; Bethea C
    J Clin Pharm Ther; 1992 Jun; 17(3):185-9. PubMed ID: 1639881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. beta-D(+) glucose-glucose oxidase-catalase for use as an antioxidant system.
    Uppoor R; Niebergall PJ
    Pharm Dev Technol; 1996 Jul; 1(2):127-34. PubMed ID: 9552339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stability of enalapril maleate in three extemporaneously prepared oral liquids.
    Nahata MC; Morosco RS; Hipple TF
    Am J Health Syst Pharm; 1998 Jun; 55(11):1155-7. PubMed ID: 9626379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acid-catalyzed inversion of sucrose in the amorphous state at very low levels of residual water.
    Shalaev EY; Lu Q; Shalaeva M; Zografi G
    Pharm Res; 2000 Mar; 17(3):366-70. PubMed ID: 10801227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Stability of some medicinal solutions with captopril].
    Imre S; Vancea S; Muntean DL; Sipos E; Cociş A; Avrigeanu V; Mircia E
    Rev Med Chir Soc Med Nat Iasi; 2008; 112(3):848-55. PubMed ID: 20201280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Stability study of an aqueous formulation of captopril at 1 mg/ml].
    Escribano García MJ; Torrado Durán S; Torrado Durán JJ
    Farm Hosp; 2005; 29(1):30-6. PubMed ID: 15773800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variations in captopril formulations used to treat children with heart failure: a survey in the United kingdom.
    Mulla H; Tofeig M; Bu'Lock F; Samani N; Pandya HC
    Arch Dis Child; 2007 May; 92(5):409-11. PubMed ID: 17363396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of lyophilized sucrose formulations of an IgG1: subvisible particle formation.
    Davis JM; Zhang N; Payne RW; Murphy BM; Abdul-Fattah AM; Matsuura JE; Herman AC; Manning MC
    Pharm Dev Technol; 2013; 18(4):883-96. PubMed ID: 22813478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pharmaceutical excipients on the stability of angiotensin-converting enzyme inhibitors in their solid dosage formulations.
    Stanisz B; Regulska K; Kania J; Garbacki P
    Drug Dev Ind Pharm; 2013 Jan; 39(1):51-61. PubMed ID: 22348774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.